News | News By Subject | News by Disease News By Date | Search News

Hyperparathyroidism News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Opko Health (OPK) Rockets on FDA Approval of Rayaldee Four Months Ahead of PDUFA Date     6/22/2016
Opko Health (OPK), Vifor Fresenius Medical Care Renal Pharma Forge $282 Million+ RAYALDEE Deal     5/9/2016
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Amgen (AMGN)'s Hormone-Imbalance Drug AMG 416 Shows Positive Results in Phase 3 Study     2/27/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
FDA Panel Recommends Approval Of NPS Pharmaceuticals, Inc. (NPSP)'s Natpara To Treat Hypoparathyroidism     9/15/2014
Good News For Amgen (AMGN) As Parathyroid Drug AMG 416 Succeeds In Phase 3 Study     8/20/2014
NPS Pharmaceuticals, Inc. (NPSP) PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism     9/20/2007
Abbott Laboratories (ABT) Announces FDA Approval Of Zemplar(R) (paricalcitol) Capsules For Earlier Treatment Of Kidney Disease Complication     5/27/2005
Genzyme Corporation (GENZ) And Bone Care International Inc. (BCII) Announce Merger Agreement For $600 Million; Adding Complementary Therapy To Renagel; Accelerates Commercial Entry Into Earlier Stages Of Chronic Kidney D     5/4/2005
Amgen (AMGN) Release: European Commission Approves Innovative First-In-Class Treatment For A Serious Complication Of Chronic Kidney Disease     10/28/2004
Abgenix (ABGX) Announces Positive Clinical Trial Results For ABX10241 Antibody Product Candidate     10/4/2004
Amgen (AMGN) Release: Mimpara (Cinacalcet HCl) Receives Positive Regulatory Opinion For Approval In Europe     7/30/2004
Abbott Laboratories' (ABT) Zemplar(R) (Paricalcitol Injection) Receives FDA Approval For Pediatric Use     5/27/2004

News from Around the Web

Press Releases
Amgen (AMGN) Release: European Commission (EC) Approves Parsabiv (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis     11/14/2016
Opko Health (OPK) Announces Third Quarter Financial And Operating Results     11/10/2015
Amgen (AMGN) Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis     11/9/2015
FDA Accepts Amgen (AMGN)'s New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide     11/9/2015
Amgen (AMGN) Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency     9/3/2015
FDA Accepts Opko Health (OPK)'s New Drug Application For Rayaldee     7/29/2015
Amgen (AMGN) CKD Drug Effective in Reducing PTH in Two Phase III Studies     5/29/2015
Amgen (AMGN) Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis     2/26/2015
NPS Pharmaceuticals, Inc. (NPSP) Release: FDA Posts Briefing Materials For Advisory Committee Meeting Reviewing Natpara® For Hypoparathyroidism     9/10/2014
Opko Health, Inc. Release: Rayaldee Phase 3 Trial Meets Primary Endpoints     8/12/2014
Rockwell Medical (RMTI) Receives FDA Approval For Calcitriol     6/23/2014
Opko Health, Inc. Completes Patient Enrollment In Third Phase 3 Trial Of RAYALDEE™     5/6/2014
Rockwell Medical (RMTI) Announces Triferic™ Iron Replacement Clinical Data Selected For Three Abstract Presentations At National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 In Las Vegas, NV     4/14/2014
Opko Health, Inc. Completes Patient Recruitment In First Phase 3 Trial Of Rayaldy™     11/15/2013
NPS Pharmaceuticals, Inc. (NPSP) Release: New Findings From the REPLACE Study Suggest Natpara Has a Beneficial Effect on Bone Health in Patients With Hypoparathyroidism     10/7/2013

//-->